Literature DB >> 16951372

Induction of RelB participates in endotoxin tolerance.

Barbara K Yoza1, Jean Y-Q Hu, Sue L Cousart, Lolita M Forrest, Charles E McCall.   

Abstract

Using a THP-1 human promonocyte model of endotoxin tolerance that simulates the sepsis leukocyte phenotype, we previously showed that tolerant cells remain responsive to LPS endotoxin with degradation of IkappaB in the cytosol and nuclear translocation and accumulation of p50 and p65 NF-kappaB transcription factors. Despite this, endotoxin-inducible NF-kappaB-dependent innate immunity genes, like IL-1beta, remained transcriptionally unresponsive in the tolerant phenotype, similar to the endotoxin tolerance observed in sepsis patients. In this study, we examined this paradox and found that RelB, another member of the NF-kappaB family, is induced during the establishment of tolerance. RelB expression correlated with IL-1beta repression, and sepsis patients showed increased RelB when compared with normal controls. Transient expression of RelB inhibited IL-1beta in endotoxin-responsive cells. In the inverse experiment, small inhibitory RNAs decreased RelB expression in tolerant cells and restored endotoxin induction of IL-1beta. When we examined tolerant cell extracts, we found transcriptionally inactive NF-kappaB p65/RelB heterodimers. Taken together, our findings demonstrate that RelB can repress proinflammatory gene expression, and suggest that RelB expression in sepsis patient blood leukocytes may play a role in the endotoxin-tolerant phenotype.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16951372     DOI: 10.4049/jimmunol.177.6.4080

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  55 in total

1.  Classical NF-kappaB activation negatively regulates noncanonical NF-kappaB-dependent CXCL12 expression.

Authors:  Lisa A Madge; Michael J May
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

Review 2.  Gene-specific epigenetic regulation in serious infections with systemic inflammation.

Authors:  Charles E McCall; Barbara Yoza; Tiefu Liu; Mohamed El Gazzar
Journal:  J Innate Immun       Date:  2010-04-27       Impact factor: 7.349

Review 3.  The nuclear factor NF-kappaB pathway in inflammation.

Authors:  Toby Lawrence
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-10-07       Impact factor: 10.005

4.  Facultative heterochromatin formation at the IL-1 beta promoter in LPS tolerance and sepsis.

Authors:  Barbara K Yoza; Charles E McCall
Journal:  Cytokine       Date:  2011-02       Impact factor: 3.861

Review 5.  NF-κB, the first quarter-century: remarkable progress and outstanding questions.

Authors:  Matthew S Hayden; Sankar Ghosh
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

6.  Pellino-3 promotes endotoxin tolerance and acts as a negative regulator of TLR2 and TLR4 signaling.

Authors:  Michael B Murphy; Yanbao Xiong; Goutham Pattabiraman; Tissa T Manavalan; Fu Qiu; Andrei E Medvedev
Journal:  J Leukoc Biol       Date:  2015-08-26       Impact factor: 4.962

7.  Deacetylation by SIRT1 Reprograms Inflammation and Cancer.

Authors:  Tie Fu Liu; Charles E McCall
Journal:  Genes Cancer       Date:  2013-03

8.  Aryl hydrocarbon receptor is necessary to protect fetal human pulmonary microvascular endothelial cells against hyperoxic injury: Mechanistic roles of antioxidant enzymes and RelB.

Authors:  Shaojie Zhang; Ananddeep Patel; Chun Chu; Weiwu Jiang; Lihua Wang; Stephen E Welty; Bhagavatula Moorthy; Binoy Shivanna
Journal:  Toxicol Appl Pharmacol       Date:  2015-03-29       Impact factor: 4.219

9.  Dynamic protein associations define two phases of IL-1beta transcriptional activation.

Authors:  Yue Zhang; Simona Saccani; Hyunjin Shin; Barbara S Nikolajczyk
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Dynamic and selective nucleosome repositioning during endotoxin tolerance.

Authors:  Mohamed El Gazzar; Tiefu Liu; Barbara K Yoza; Charles E McCall
Journal:  J Biol Chem       Date:  2009-11-09       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.